Rosuvastatin (BioDeep_00000017873)

   

human metabolite blood metabolite


代谢物信息卡片


(3R,5S,6E)-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulphonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid

化学式: C22H28FN3O6S (481.16827600000005)
中文名称: 罗伐他汀
谱图信息: 最多检出来源 Homo sapiens(blood) 92.31%

分子结构信息

SMILES: CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
InChI: InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1

描述信息

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor
D009676 - Noxae > D000963 - Antimetabolites
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

16 个代谢物同义名

(3R,5S,6E)-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulphonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulphonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoate; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoate; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoate; Calcium, rosuvastatin; Rosuvastatin calcium; (3R,5R)-Rosuvastatin; Rosuvastatin; Creston; Crestor; ZD-4522



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Anna Braszak-Cymerman, Marta K Walczak, Mary-Tiffany Oduah, Aleksandra Ludziejewska, Wiesław Bryl. Comparison of the pleiotropic effect of atorvastatin and rosuvastatin on postmenopausal changes in bone turnover: A randomized comparative study. Medicine. 2024 May; 103(19):e38122. doi: 10.1097/md.0000000000038122. [PMID: 38728464]
  • Xuxian Lv, Xudong Liu, Yanfang Peng, Wenbin Li, Jianing Wang, Xiaofeng Chen, Junjie Lei, Chaogang Tang, Shijian Luo, Weihua Mai, Yiming Cai, Qian Fan, Chenhao Liu, Lei Zhang. Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2024 May; 33(5):107647. doi: 10.1016/j.jstrokecerebrovasdis.2024.107647. [PMID: 38431112]
  • Emrush Rexhaj, Sarah Bär, Rodrigo Soria, Yasushi Ueki, Jonas D Häner, Tatsuhiko Otsuka, Raminta Kavaliauskaite, George Cm Siontis, Stefan Stortecky, Hiroki Shibutani, David Spirk, Thomas Engstrøm, Irene Lang, Laura Morf, Maria Ambühl, Stephan Windecker, Sylvain Losdat, Konstantinos C Koskinas, Lorenz Räber. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy. Atherosclerosis. 2024 May; 392(?):117504. doi: 10.1016/j.atherosclerosis.2024.117504. [PMID: 38513436]
  • Yang Liu, Yuan Chen, Baozhu Wei, Hang Li, Yuanyuan Peng, Zhi Luo. Impacts of ABCG2 loss of function variant (p. Gln141Lys, c.421 C > A, rs2231142) on lipid levels and statin efficiency: a systematic review and meta-analysis. BMC cardiovascular disorders. 2024 Apr; 24(1):202. doi: 10.1186/s12872-024-03821-2. [PMID: 38589776]
  • Chandra Mani Adhikari, Dipanker Prajapati, Birat Timalsena, Amrit Bogati, Barkadin Khan, Sajjad Safi, Jagat Adhikari, Vijay Ghimire. Use of Statin and Target Low-density lipoprotein cholesterol attainment among post-ST elevation myocardial infarction patients in Shahid Gangalal National Heart Centre, Kathmandu, Nepal. Journal of Nepal Health Research Council. 2024 Mar; 21(4):564-572. doi: 10.33314/jnhrc.v21i4.4754. [PMID: 38616584]
  • Hacer Kayhan Kaya, Berjan Demirtas, Beran Yokus, Dilek Aygün Kesim, Ezel Tasdemir, Abdurrahman Sermet. Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model. Acta pharmaceutica (Zagreb, Croatia). 2024 Mar; 74(1):117-130. doi: 10.2478/acph-2024-0001. [PMID: 38554383]
  • James M Backes, Daniel E Hilleman. Lipid lowering therapy: implications of recent clinical trials. Future cardiology. 2024 02; 20(2):89-98. doi: 10.2217/fca-2023-0132. [PMID: 38226457]
  • Sang-Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial. Frontiers in endocrinology. 2024; 15(?):1336357. doi: 10.3389/fendo.2024.1336357. [PMID: 38586464]
  • Lyudmila Kravchenko, Liana Unhurian, Svetlana K Tiuzhinska, Yana Ivanova, Maya Obrazenko, Liudmyla Zahorodnya, Tetiana Yamilova. Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti. 2024; 72(6):297-303. doi: ". [PMID: 38346907]
  • Ji Hye Han, Kyong Hye Joung, Jun Choul Lee, Ok Soon Kim, Sorim Choung, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Ju Hee Lee, Bon Jeong Ku, Hyun Jin Kim. Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus. Diabetes & metabolism journal. 2024 Jan; 48(1):112-121. doi: 10.4093/dmj.2022.0402. [PMID: 38173371]
  • Yura Kang, Jung Mi Park, Sang-Hak Lee. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review. Yonsei medical journal. 2024 Jan; 65(1):19-26. doi: 10.3349/ymj.2023.0285. [PMID: 38154476]
  • Anna Borioni, Francesca Romana Mammone, Roberta Risoluti, Alessia Panusa, Marco Pierini, Roberto Cirilli. Insight into the photolytic degradation products of Rosuvastatin: Full chiral and structural elucidation and conversion kinetics by a combined chromatographic, spectroscopic and theoretical approach. Journal of pharmaceutical and biomedical analysis. 2023 Nov; 236(?):115636. doi: 10.1016/j.jpba.2023.115636. [PMID: 37657179]
  • Chang-Jiang Deng, Ju Yan, Ying-Ying Zheng, Ting-Ting Wu, Ying Pan, Xian-Geng Hou, Si-Fan Wang, Subinur Sirajidin, Mikereyi Aimaitijiang, Xiang Xie. Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials. BMJ open. 2023 11; 13(11):e070827. doi: 10.1136/bmjopen-2022-070827. [PMID: 37967998]
  • Hugues Beaufrère, Trinita Barboza, Alysha Burnett, Ken D Stark, R Darren Wood. Effects of Atorvastatin and Rosuvastatin on Blood Lipids in Quaker Parrots (Myiopsitta monachus). Journal of avian medicine and surgery. 2023 Nov; 37(3):199-208. doi: 10.1647/22-00014. [PMID: 37962313]
  • Jun Sung Moon, Il Rae Park, Sang Soo Kim, Hye Soon Kim, Nam Hoon Kim, Sin Gon Kim, Seung Hyun Ko, Ji Hyun Lee, Inkyu Lee, Bo Kyeong Lee, Kyu Chang Won. The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study. Diabetes & metabolism journal. 2023 11; 47(6):818-825. doi: 10.4093/dmj.2023.0171. [PMID: 38043782]
  • Argyroula Kechagia, Natalia Manousi, Abuzar Kabir, Kenneth G Furton, Constantinos K Zacharis. Fabricating a designer capsule phase microextraction platform based on sol-gel Carbowax 20M-zwitterionic ionic liquid composite sorbent for the extraction of lipid-lowering drugs from human urine samples. Mikrochimica acta. 2023 10; 190(11):428. doi: 10.1007/s00604-023-05998-3. [PMID: 37796344]
  • Joanna Lewek, Jacek Niedziela, Piotr Desperak, Krzysztof Dyrbuś, Tadeusz Osadnik, Piotr Jankowski, Adam Witkowski, Agata Bielecka-Dąbrowa, Dariusz Dudek, Marek Gierlotka, Mariusz Gąsior, Maciej Banach. Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data. Journal of the American Heart Association. 2023 09; 12(18):e030414. doi: 10.1161/jaha.123.030414. [PMID: 37671618]
  • Stephen P Adams, Nima Alaeiilkhchi, Sara Tasnim, James M Wright. Pravastatin for lowering lipids. The Cochrane database of systematic reviews. 2023 09; 9(?):CD013673. doi: 10.1002/14651858.cd013673.pub2. [PMID: 37721222]
  • Ana Vavlukis, Kristina Mladenovska, Katarina Davalieva, Marija Vavlukis, Aleksandar Dimovski. Rosuvastatin effects on the HDL proteome in hyperlipidemic patients. Acta pharmaceutica (Zagreb, Croatia). 2023 Sep; 73(3):363-384. doi: 10.2478/acph-2023-0034. [PMID: 37708957]
  • Seung-Jun Lee, Jung-Joon Cha, Woong Gil Choi, Wang-Soo Lee, Jin-Ok Jeong, Seonghoon Choi, Yoon-Haeng Cho, Woojung Park, Chang-Hwan Yoon, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Soon Jun Hong, Jung-Sun Kim. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial. JAMA cardiology. 2023 09; 8(9):853-858. doi: 10.1001/jamacardio.2023.2222. [PMID: 37531130]
  • Caroline Nb Clezar, Carolina Dq Flumignan, Nicolle Cassola, Luis Cu Nakano, Virginia Fm Trevisani, Ronald Lg Flumignan. Pharmacological interventions for asymptomatic carotid stenosis. The Cochrane database of systematic reviews. 2023 Aug; 8(?):CD013573. doi: 10.1002/14651858.cd013573.pub2. [PMID: 37565307]
  • Seung-Jun Lee, Jae Hong Joo, Sohee Park, Choongki Kim, Dong-Woo Choi, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Chung-Mo Nam, Myeong-Ki Hong. Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2023 08; 82(5):401-410. doi: 10.1016/j.jacc.2023.05.042. [PMID: 37495276]
  • Oğuzhan Birdal, Mehmet Saygı, Remziye Doğan, Ozan Tezen, Ali Karagöz, İbrahim Halil Tanboğa. Risk of Venous Thromboembolism with Statins: Evidence Gathered via a Network Meta-analysis. Balkan medical journal. 2023 07; ?(?):. doi: 10.4274/balkanmedj.galenos.2023.2023-5-26. [PMID: 37519020]
  • Stanislav Kononov, Iuliia Azarova, Elena Klyosova, Marina Bykanova, Mikhail Churnosov, Maria Solodilova, Alexey Polonikov. Lipid-Associated GWAS Loci Predict Antiatherogenic Effects of Rosuvastatin in Patients with Coronary Artery Disease. Genes. 2023 06; 14(6):. doi: 10.3390/genes14061259. [PMID: 37372439]
  • Mohammad Taghi Gorji, Fariba Alaei-Shahmiri, Gisoo Darban Hosseini Amirkhiz, Seyed Hashem Sezavar, Mojtaba Malek, Mohammad E Khamseh. Appropriateness of Intensive Statin Treatment in People with Type Two Diabetes and Mild Hypercholesterolemia: A Randomized Clinical Trial. Archives of Iranian medicine. 2023 Jun; 26(6):290-299. doi: 10.34172/aim.2023.45. [PMID: 38310429]
  • Xue Bai, Xingzhen Long, Fang Song, Baolin Chen, Changcheng Sheng, Cailin Tang, Li Li, Jiaxing Zhang, Rui Zhang, Jiquan Zhang, Jiali Li. High doses of rosuvastatin induce impaired branched-chain amino acid catabolism and lead to insulin resistance. Experimental physiology. 2023 May; ?(?):. doi: 10.1113/ep090305. [PMID: 37139700]
  • M Zakria, A Hussain, N Ahmad, N Ahmed, M A Rauf, S Siraj. The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study. European review for medical and pharmacological sciences. 2023 May; 27(10):4708-4717. doi: 10.26355/eurrev_202305_32483. [PMID: 37259755]
  • Diamantis I Tsilimigras, Kalliopi Thanopoulou, Maria Salagianni, Gerasimos Siasos, Evangelos Oikonomou, Despina D Perrea, Nikolaos Nirakis, Konstantinos Filis, Konstantinos Tsioufis, Dimitrios Tousoulis, Fragiska Sigala. Rosuvastatin Attenuates Progression of Atherosclerosis and Reduces Serum IL6 and CCL2 Levels in Apolipoprotein-E-deficient Mice. In vivo (Athens, Greece). 2023 May; 37(3):994-1002. doi: 10.21873/invivo.13173. [PMID: 37103114]
  • Mehran Ebrahimi Shah-Abadi, Armin Ariaei, Fatemeh Moradi, Auob Rustamzadeh, Rastegar Rahmani Tanha, Nader Sadigh, Mohsen Marzban, Mahdi Heydari, Vahid Tavakolian Ferdousie. In Silico Interactions of Natural and Synthetic Compounds with Key Proteins Involved in Alzheimer's Disease: Prospects for Designing New Therapeutics Compound. Neurotoxicity research. 2023 Apr; ?(?):. doi: 10.1007/s12640-023-00648-1. [PMID: 37086338]
  • Routong Yang, Junhui Wu, Huan Yu, Siyue Wang, Hongbo Chen, Mengying Wang, Xueying Qin, Tao Wu, Yiqun Wu, Yonghua Hu. Is statin therapy after ischaemic stroke associated with increased intracerebral hemorrhage? The association may be dependent on intensity of statin therapy. International journal of stroke : official journal of the International Stroke Society. 2023 Apr; ?(?):17474930231172623. doi: 10.1177/17474930231172623. [PMID: 37070670]
  • Giovanna Gallo, Riccardo Sarzani, Arrigo Francesco Giuseppe Cicero, Stefano Genovese, Matteo Pirro, Luca Gallelli, Andrea Faggiano, Massimo Volpe. An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2023 Apr; ?(?):. doi: 10.1007/s40292-023-00570-9. [PMID: 37020154]
  • Leonie Schoch, Pablo Sutelman, Rosa Suades, Lina Badimon, Isabel Moreno-Indias, Gemma Vilahur. The gut microbiome dysbiosis is recovered by restoring a normal diet in hypercholesterolemic pigs. European journal of clinical investigation. 2023 Apr; 53(4):e13927. doi: 10.1111/eci.13927. [PMID: 36453873]
  • Bahar Arican Tarim, Francesco Fici, Istemihan Tengiz, Saadet Avunduk, Yurdaer Ozcan, Gokhan Faikoglu, Elif Ari, Nicolás Roberto Robles, Guido Grassi. Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study. Yonsei medical journal. 2023 Mar; 64(3):175-180. doi: 10.3349/ymj.2022.0287. [PMID: 36825343]
  • A V Susekov. [Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin]. Kardiologiia. 2023 Feb; 63(2):59-67. doi: 10.18087/cardio.2023.2.n2407. [PMID: 36880145]
  • Juwon Kim, Danbee Kang, Hyejeong Park, Minwoong Kang, Ki Hong Choi, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Young Bin Song, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Eliseo Guallar, Juhee Cho, Joo-Yong Hahn. Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study. Cardiovascular drugs and therapy. 2023 02; 37(1):141-150. doi: 10.1007/s10557-021-07256-1. [PMID: 34533691]
  • Luke J Laffin, Dennis Bruemmer, Michelle Garcia, Danielle M Brennan, Ellen McErlean, Douglas S Jacoby, Erin D Michos, Paul M Ridker, Tracy Y Wang, Karol E Watson, Howard G Hutchinson, Steven E Nissen. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. Journal of the American College of Cardiology. 2023 01; 81(1):1-12. doi: 10.1016/j.jacc.2022.10.013. [PMID: 36351465]
  • Miao-Ping Hong, Wei-Fen Chen, Jie-Hao Wu, Tai-Shan Kang, Shun-Po He, Qing-Wei Yang. Correlation between lipid-lowering therapy and cerebral microbleeds. Clinical hemorheology and microcirculation. 2023; 85(1):59-71. doi: 10.3233/ch-231833. [PMID: 37355888]
  • Kwang Je Lee, Jae-Kean Ryu, Yun-Hyeong Cho, Won Yong Shin, Jeong Su Kim, Young Won Yoon, Ji Yong Jang, Won Ho Kim, Jong Wook Beom, Seok-Min Kang. Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study. Drug design, development and therapy. 2023; 17(?):1047-1062. doi: 10.2147/dddt.s391288. [PMID: 37051292]
  • Ewelina Woźniak, Marlena Broncel, Mateusz Niedzielski, Agnieszka Woźniak, Paulina Gorzelak-Pabiś. The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells. PloS one. 2023; 18(2):e0280741. doi: 10.1371/journal.pone.0280741. [PMID: 36753488]
  • Khalifa Alrajeh, Youssef M Roman. The frequency of rs2231142 in ABCG2 among Asian subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics. 2023 01; 24(1):15-26. doi: 10.2217/pgs-2022-0155. [PMID: 36651271]
  • Robert Krysiak, Karolina Kowalcze, Bogusław Okopień. Rosuvastatin potentiates the thyrotropin-lowering effect of metformin in men with non-autoimmune subclinical hypothyroidism and prediabetes. Journal of clinical pharmacy and therapeutics. 2022 Dec; 47(12):2030-2040. doi: 10.1111/jcpt.13746. [PMID: 35899679]
  • Martin B Mortensen, Niels-Peter Sand, Martin Busk, Jesper M Jensen, Erik L Grove, Damini Dey, Nadia Iraqi, Adam Updegrove, Tim Fonte, Ole N Mathiassen, Susanne Hosbond, Hans E Bøtker, Jonathon Leipsic, Jagat Narula, Bjarne L Nørgaard. Influence of intensive lipid-lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study. Clinical cardiology. 2022 Oct; 45(10):986-994. doi: 10.1002/clc.23895. [PMID: 36056636]
  • Huaguang Zheng, Hongwei Li, Yilong Wang, Zhanquan Li, Bo Hu, Xiaogang Li, Lu Fu, Hongtao Hu, Zhiyu Nie, Bilian Zhao, Di Wei, Björn W Karlson, Michiel L Bots, XiangWen Meng, Yundai Chen, Yongjun Wang. Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study. Stroke. 2022 10; 53(10):3004-3013. doi: 10.1161/strokeaha.120.031877. [PMID: 36017704]
  • Sijin He, Qigang Chen, Zhicong Jing, Lihua Gu, Kaixuan Luo. Avellis syndrome with ipsilateral prosopalgia, glossopharyngeal neuralgia, and central post-stroke pain: A case report and literature review. Medicine. 2022 Sep; 101(39):e30669. doi: 10.1097/md.0000000000030669. [PMID: 36181064]
  • Mahmood Salim Yaseen, Nidhal Mohammed Ali. The effect of bempedoic acid an ATP-citrate lyase inhibitor on cardiovascular risk factors in rats with experimentally induced myocardial infarction and hyperlipidemia. Cellular and molecular biology (Noisy-le-Grand, France). 2022 Sep; 68(10):94-99. doi: 10.14715/cmb/2022.68.10.15. [PMID: 37114265]
  • Caiping Zhang, Debiao Xiang, Qian Zhao, Susu Jiang, Chuyao Wang, Huixian Yang, Ying Huang, Yulin Yuan, Xuanyou Liu, Zhixin Huang, Yaling Zeng, Hongyan Wen, Shiyin Long, Hong Hao, Qinhui Tuo, Zhenguo Liu, Duanfang Liao. Curcumin nicotinate decreases serum LDL cholesterol through LDL receptor-mediated mechanism. European journal of pharmacology. 2022 Sep; 931(?):175195. doi: 10.1016/j.ejphar.2022.175195. [PMID: 35964656]
  • Mohamed Ibrahim Mohamed Fahmy, Rabab Hamed Sayed, Muhammad Farag El-Yamany, Reham El-Naggar, Hesham A Eliwa. Rosuvastatin and co-enzyme Q10 improve high-fat and high-fructose diet-induced metabolic syndrome in rats via ameliorating inflammatory and oxidative burden. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Sep; 153(?):113526. doi: 10.1016/j.biopha.2022.113526. [PMID: 36076607]
  • Jun Choul Lee, Kyong Hye Joung, Ji Min Kim, Seon Mee Kang, Hyun Jin Kim, Bon Jeong Ku. Effect of cholesterol-lowering agents on soluble epidermal growth factor receptor level in type 2 diabetes and hypercholesterolemia. Medicine. 2022 Aug; 101(34):e30287. doi: 10.1097/md.0000000000030287. [PMID: 36042588]
  • Rosangela A Hoshi, Yanyan Liu, Heike Luttmann-Gibson, Saumya Tiwari, Franco Giulianini, Allen M Andres, Jeramie D Watrous, Nancy R Cook, Karen H Costenbader, Olivia I Okereke, Paul M Ridker, JoAnn E Manson, I-Min Lee, Manickavasagar Vinayagamoorthy, Susan Cheng, Trisha Copeland, Mohit Jain, Daniel I Chasman, Olga V Demler, Samia Mora. Association of Physical Activity With Bioactive Lipids and Cardiovascular Events. Circulation research. 2022 08; 131(4):e84-e99. doi: 10.1161/circresaha.122.320952. [PMID: 35862024]
  • Leonie Schoch, Pablo Sutelman, Rosa Suades, Laura Casani, Teresa Padro, Lina Badimon, Gemma Vilahur. Hypercholesterolemia-Induced HDL Dysfunction Can Be Reversed: The Impact of Diet and Statin Treatment in a Preclinical Animal Model. International journal of molecular sciences. 2022 Aug; 23(15):. doi: 10.3390/ijms23158596. [PMID: 35955730]
  • Tsung-Hui Wu, I-Te Lee, Low-Tone Ho, Wayne H-H Sheu, Chii-Min Hwu. Combined lipid goal attainment in patients with type 2 diabetes and dyslipidemia: A head-to-head comparative trial of statins. Journal of the Chinese Medical Association : JCMA. 2022 08; 85(8):831-838. doi: 10.1097/jcma.0000000000000765. [PMID: 35727095]
  • Mubashar Rehman, Muhammad Ziaullah Khan, Muhammad Tayyab, Asadullah Madni, Qandeel Khalid. Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs. Journal of visualized experiments : JoVE. 2022 07; ?(185):. doi: 10.3791/63995. [PMID: 35969097]
  • Xiaowei Xiong, Jian Zhou, Qiang Fu, Xiaowei Xu, Shaobin Wei, Shenghua Yang, Buxing Chen. The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy. Lipids in health and disease. 2022 Jul; 21(1):60. doi: 10.1186/s12944-022-01673-3. [PMID: 35864500]
  • Toktam Alirezaei, Haniyeh Sattari, Rana Irilouzadian. Significant decrease in plasmad-dimer levels and mean platelet volume after a 3-month treatment with rosuvastatin in patients with venous thromboembolism. Clinical cardiology. 2022 Jul; 45(7):717-722. doi: 10.1002/clc.23833. [PMID: 35481712]
  • Muhammed A Saad, Muhammad Y Al-Shorbagy, Hany H Arab. Targeting the TLR4/NF-κΒ Axis and NLRP1/3 Inflammasomes by Rosuvastatin: A Role in Impeding Ovariectomy-Induced Cognitive Decline Neuropathology in Rats. Molecular neurobiology. 2022 Jul; 59(7):4562-4577. doi: 10.1007/s12035-022-02852-0. [PMID: 35578102]
  • R X Du, J M Cai, Q J Wang, L M Luo, X N Wang, R H Cao, H M Wu, P Ye. [Effects of moderate dose rosuvastatin on carotid plaque in patients with diabetes mellitus evaluated by magnetic resonance imaging]. Zhonghua xin xue guan bing za zhi. 2022 Jun; 50(6):570-576. doi: 10.3760/cma.j.cn112148-20220225-00136. [PMID: 35705466]
  • Ferran Trias, Xavier Pintó, Emili Corbella, Manuel Suárez-Tembra, Antonio Ruíz-García, José Luis Díaz-Díaz, Elena Sánchez-Ruíz-Granado, Itziar Sarasa, Raul Martínez-Porqueras, Maria Angeles Rodríguez-Sánchez, Xavier Corbella. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Medicina clinica. 2022 06; 158(11):531-539. doi: 10.1016/j.medcli.2021.06.018. [PMID: 34517987]
  • Tatsuki Mochizuki, Maciej J Zamek-Gliszczynski, Kenta Yoshida, Jialin Mao, Kunal Taskar, Hideki Hirabayashi, Xiaoyan Chu, Yurong Lai, Tadayuki Takashima, Kevin Rockich, Yoshiyuki Yamaura, Kaku Fujiwara, Tadahaya Mizuno, Kazuya Maeda, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. Clinical pharmacology and therapeutics. 2022 06; 111(6):1315-1323. doi: 10.1002/cpt.2584. [PMID: 35292967]
  • William A Murphy, Nan Lin, Amy Damask, Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Poulabi Banerjee, Sergio Fazio, Garen Manvelian, Robert Pordy, Alan R Shuldiner, Charles Paulding. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. Circulation. Genomic and precision medicine. 2022 06; 15(3):e003503. doi: 10.1161/circgen.121.003503. [PMID: 35543701]
  • Srinivasu Poondru, Vitalii Ghicavii, Reza Khosravan, Pooja Manchandani, Nakyo Heo, Selina Moy, Tomasz Wojtkowski, Melanie Patton, Gabriel P Haas. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clinical and translational science. 2022 05; 15(5):1131-1142. doi: 10.1111/cts.13229. [PMID: 35118821]
  • Ana Vavlukis, Marija Vavlukis, Kristina Mladenovska, Aleksandar Dimovski, Natàlia Muñoz-García, Victoria de Santisteban Villaplana, Teresa Padro, Lina Badimon. Antioxidative Effects of Rosuvastatin in Low-to-Moderate Cardiovascular Risk Subjects. Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki). 2022 Apr; 43(1):65-75. doi: 10.2478/prilozi-2022-0007. [PMID: 35451294]
  • Cathrine Ramberg, Kristian Hindberg, Joseph S Biedermann, Suzanne C Cannegieter, Felix J van der Meer, Omri Snir, Frank W G Leebeek, Marieke J H A Kruip, John-Bjarne Hansen, Willem M Lijfering. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of thrombosis and haemostasis : JTH. 2022 04; 20(4):877-887. doi: 10.1111/jth.15626. [PMID: 34953155]
  • Dorien Groenendaal-van de Meent, Martin den Adel, Virginie Kerbusch, Jan van Dijk, Tomohisa Shibata, Kota Kato, Marloes Schaddelee. Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies. Clinical pharmacology in drug development. 2022 04; 11(4):486-501. doi: 10.1002/cpdd.1076. [PMID: 35182045]
  • Yiming Cheng, Xiaomin Wang, Zeen Tong, Josephine Reyes, Leon Carayannopoulos, Simon Zhou, Yan Li. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Journal of clinical pharmacology. 2022 04; 62(4):494-504. doi: 10.1002/jcph.1979. [PMID: 34617279]
  • Elisenda Climent, Ana M Bea, David Benaiges, Ángel Brea-Hernando, Xavier Pintó, Manuel Suárez-Tembra, Verónica Perea, Núria Plana, Francisco Blanco-Vaca, Juan Pedro-Botet. LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. Cardiovascular drugs and therapy. 2022 04; 36(2):301-308. doi: 10.1007/s10557-020-07137-z. [PMID: 33555511]
  • Gustavo A Yerino, Ethel C Feleder, Emilia K Halabe, Liliana Diaz, Mario Sakson, Mariana Iglesias, Tobías Haddad, Emilio Roldán, Nélida Mondelo. Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects. International journal of clinical pharmacology and therapeutics. 2022 Apr; 60(4):192-206. doi: 10.5414/cp204026. [PMID: 35103587]
  • Yi Liu, Bing Han. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China. Transplant immunology. 2022 04; 71(?):101444. doi: 10.1016/j.trim.2021.101444. [PMID: 34375677]
  • Gehan H Heeba, Marwa A M Ali, Azza A K El-Sheikh. Rosuvastatin Induces Renal HO-1 Activity and Expression Levels as a Main Protective Mechanism against STZ-Induced Diabetic Nephropathy. Medicina (Kaunas, Lithuania). 2022 Mar; 58(3):. doi: 10.3390/medicina58030425. [PMID: 35334601]
  • Jun Choul Lee, Ji Min Kim, Kyong Hye Joung, Seon Mee Kang, Hyun Jin Kim, Bon Jeong Ku. Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia. The Journal of international medical research. 2022 Mar; 50(3):3000605221085079. doi: 10.1177/03000605221085079. [PMID: 35301888]
  • Zhen Zhou, Andrea J Curtis, Michael E Ernst, Joanne Ryan, Sophia Zoungas, Rory Wolfe, John J McNeil, Anne M Murray, Christopher M Reid, Enayet K Chowdhury, Robyn L Woods, Andrew M Tonkin, Mark R Nelson. Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. European journal of clinical pharmacology. 2022 Mar; 78(3):467-476. doi: 10.1007/s00228-021-03239-1. [PMID: 34698889]
  • Wenjie Zhu, Meizhu Yan, Haibin Cao, Jun Zhou, Zhongqing Xu. Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients. Cellular and molecular biology (Noisy-le-Grand, France). 2022 Feb; 68(2):64-69. doi: 10.14715/cmb/2022.68.2.10. [PMID: 35869734]
  • Philip Joseph, Robert Glynn, Eva Lonn, Chinthanie Ramasundarahettige, John Eikelboom, Jean MacFadyen, Paul Ridker, Salim Yusuf. Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovascular research. 2022 02; 118(3):897-903. doi: 10.1093/cvr/cvab078. [PMID: 33705531]
  • Takuhiro Shirakawa, Koichiro Fujisue, Shinichi Nakamura, Nobuyasu Yamamoto, Shuichi Oshima, Toshiyuki Matsumura, Ryusuke Tsunoda, Nobutaka Hirai, Shunichi Koide, Shinji Tayama, Koichi Kikuta, Toyoki Hirose, Hideki Maruyama, Kazuteru Fujimoto, Ichiro Kajiwara, Tomohiro Sakamoto, Koichi Nakao, Naritsugu Sakaino, Yasuhiro Nagayoshi, Jun Hokamaki, Hideki Shimomura, Kenji Sakamoto, Eiichiro Yamamoto, Yasuhiro Izumiya, Koichi Kaikita, Seiji Hokimoto, Hisao Ogawa, Kenichi Tsujita. Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial. Journal of atherosclerosis and thrombosis. 2022 Feb; 29(2):229-241. doi: 10.5551/jat.59477. [PMID: 33408315]
  • Emi Kimoto, Chester Costales, Mark A West, Yi-An Bi, Manoli Vourvahis, A David Rodrigues, Manthena V S Varma. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions. Clinical pharmacology and therapeutics. 2022 02; 111(2):404-415. doi: 10.1002/cpt.2434. [PMID: 34605015]
  • Kacey Anderson, Cara H Nelson, Qi Gong, Muhsen Alani, Thomas Tarnowski, Ahmed A Othman. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants. Clinical pharmacology in drug development. 2022 02; 11(2):235-245. doi: 10.1002/cpdd.1015. [PMID: 34468080]
  • Jeonghyeon Moon, Seon-Yeong Lee, Hyun Sik Na, A Ram Lee, Keun-Hyung Cho, Jeong Won Choi, Sung-Hwan Park, Mi-La Cho. Ezetimibe ameliorates clinical symptoms in a mouse model of ankylosing spondylitis associated with suppression of Th17 differentiation. Frontiers in immunology. 2022; 13(?):922531. doi: 10.3389/fimmu.2022.922531. [PMID: 36059546]
  • Seyong Chung, Young-Guk Ko, Jung Sun Kim, Byeong-Keuk Kim, Chul-Min Ahn, Sungha Park, Sung-Jin Hong, Sang-Hak Lee, Donghoon Choi. Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: The randomized FIXAR study. Cardiology journal. 2022; 29(5):815-823. doi: 10.5603/cj.a2020.0167. [PMID: 33346375]
  • Khalid M El-Say, Raed I Felimban, Hossam H Tayeb, Adeel G Chaudhary, Abdelsattar M Omar, Waleed Y Rizg, Fuad H Alnadwi, Fathy I Abd-Allah, Tarek A Ahmed. Pairing 3D-Printing with Nanotechnology to Manage Metabolic Syndrome. International journal of nanomedicine. 2022; 17(?):1783-1801. doi: 10.2147/ijn.s357356. [PMID: 35479768]
  • Hana Rosolová. Advances of the contemporary treatment of hypertension and hypercholesterolemia by a new fixed combination. Vnitrni lekarstvi. 2022; 68(1):64-67. doi: NULL. [PMID: 35459349]
  • Maya R Chilbert, Dylan VanDuyn, Sara Salah, Collin M Clark, Qing Ma. Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. Drug design, development and therapy. 2022; 16(?):2177-2186. doi: 10.2147/dddt.s332352. [PMID: 35832642]
  • Riham M Karkeet, Abdelrahman N Zekri, Mohamed M Sayed-Ahmed, Ghada M Sherif, Salem E Salem, Ahmed Abdelbary, Mariam A Fouad, Sherif Y Saad. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial. PloS one. 2022; 17(12):e0278282. doi: 10.1371/journal.pone.0278282. [PMID: 36480560]
  • Zahra Lotfollahi, Ana P Q Mello, Francisco A H Fonseca, Luciene O Machado, Andressa F Mathias, Maria C Izar, Nagila R T Damasceno, Cristiano L P Oliveira, Antônio M F Neto. Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction. PloS one. 2022; 17(8):e0273292. doi: 10.1371/journal.pone.0273292. [PMID: 36040917]
  • Faheem Sultan, Rajdeep Kaur, Najeeb U Tarfain, Arshad H Mir, Vinod K Dumka, Suresh K Sharma, Simrat P Singh Saini. Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-α expressions affecting oxidative/nitrosative stress and inflammation. Human & experimental toxicology. 2022 Jan; 41(?):9603271211066065. doi: 10.1177/09603271211066065. [PMID: 35130744]
  • Jianli Fu, Ting Wang, Botao Li, Na Zhao. The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. Disease markers. 2022; 2022(?):1111438. doi: 10.1155/2022/1111438. [PMID: 36284992]
  • Jianzhong Zhu, Shan Wang, Zhenqiu Chen, Qiqi Cheng. Efficacy of Rosuvastatin Combined with rt-PA Intravenous Thrombolytic Therapy for Elderly Acute Ischemic Stroke Patients. Computational and mathematical methods in medicine. 2022; 2022(?):9403693. doi: 10.1155/2022/9403693. [PMID: 35756414]
  • Stanislav Kononov, Galina Mal, Iuliia Azarova, Elena Klyosova, Marina Bykanova, Mikhail Churnosov, Alexey Polonikov. Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk. Pharmacogenomics. 2022 01; 23(1):15-34. doi: 10.2217/pgs-2021-0097. [PMID: 34905955]
  • Sheida Afkham, Jalal Hanaee, Mostafa Zakariazadeh, Farzaneh Fathi, Samira Shafiee, Somaieh Soltani. Molecular mechanism and thermodynamic study of Rosuvastatin interaction with human serum albumin using a surface plasmon resonance method combined with a multi-spectroscopic, and molecular modeling approach. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2022 Jan; 168(?):106005. doi: 10.1016/j.ejps.2021.106005. [PMID: 34688823]
  • Qing Sun, Li Li, Quan Zhou. Effects of Ethanolic Extract of Schisandra sphenanthera on the Pharmacokinetics of Rosuvastatin in Rats. Drug design, development and therapy. 2022; 16(?):1473-1481. doi: 10.2147/dddt.s364234. [PMID: 35607596]
  • Seyyed Majid Eslami, Laleh Khorshidi, Maryam Ghasemi, Amir Rashidian, Mahdi Mirghazanfari, Akram Nezhadi, Mohsen Chamanara, Ruhollah Mirjani. Protective effects of atorvastatin and rosuvastatin on 3,4-methylenedioxymethamphetamine (MDMA)-induced spatial learning and memory impairment. Inflammopharmacology. 2021 Dec; 29(6):1807-1818. doi: 10.1007/s10787-021-00891-y. [PMID: 34780009]
  • Saeideh Saadat, Mohammad Hossein Boskabady. Anti-inflammatory and Antioxidant Effects of Rosuvastatin on Asthmatic, Hyperlipidemic, and Asthmatic-Hyperlipidemic Rat Models. Inflammation. 2021 Dec; 44(6):2279-2290. doi: 10.1007/s10753-021-01499-8. [PMID: 34226988]
  • Ashish Yashwantrao Pawar, Sagar S Patil, Prajakta S More, Pallavi R Jadhav, Snehal R Bhavar. Preparation and characterization of nanocochelate by using phosphatidylcholine as lipid carrier for enhancement of permeability and bioavailability of rosuvastatin. Drug development and industrial pharmacy. 2021 Dec; 47(12):2004-2012. doi: 10.1080/03639045.2022.2087081. [PMID: 35658764]
  • N V Radyukhina, N Yu Ruleva, A Yu Filatova, T I Aref'eva. Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (Statins) Suppress Proliferation and Motility of Human CD4+ T Lymphocytes in Culture. Bulletin of experimental biology and medicine. 2021 Dec; 172(2):137-142. doi: 10.1007/s10517-021-05350-w. [PMID: 34855095]
  • Ken Ogasawara, Rebecca N Wood-Horrall, Mark Thomas, Michael Thomas, Liangang Liu, Mary Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. Cancer chemotherapy and pharmacology. 2021 12; 88(6):941-952. doi: 10.1007/s00280-021-04346-7. [PMID: 34477937]
  • Andrey Sivkov, Natalya Chernus, Roman Gorenkov, Sergey Sivkov, Svetlana Sivkova, Tamara Savina. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia. Lipids in health and disease. 2021 Nov; 20(1):157. doi: 10.1186/s12944-021-01586-7. [PMID: 34749751]
  • Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee, Sandeep Dutta. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model. Clinical and translational science. 2021 11; 14(6):2510-2520. doi: 10.1111/cts.13118. [PMID: 34415673]
  • Ki Young Huh, Sang Won Lee, Si Beum Lee, Kyung Tae Kim, In-Jin Jang, SeungHwan Lee. Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan. Clinical pharmacology in drug development. 2021 11; 10(11):1290-1296. doi: 10.1002/cpdd.926. [PMID: 33647189]
  • Mohamed-Eslam F Mohamed, Sheryl Coppola, Tian Feng, Heidi S Camp, Elaine Kim, Ahmed A Othman. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects. Clinical pharmacology in drug development. 2021 11; 10(11):1335-1344. doi: 10.1002/cpdd.957. [PMID: 34109764]
  • Nikolaos Sabanis, Eleni Paschou, Aikaterini Drylli, Panagiota Papanikolaou, Georgios Zagkotsis. Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt. CEN case reports. 2021 11; 10(4):570-575. doi: 10.1007/s13730-021-00598-7. [PMID: 34028728]
  • Mingxiang Liao, Krzysztof G Jeziorski, Monika Tomaszewska-Kiecana, István Láng, Marek Jasiówka, Viera Skarbová, Piotr Centkowski, Rodryg Ramlau, Maria Górnaś, John Lee, Sarah Edwards, Jenn Habeck, Eileen Nash, Nikolay Grechko, Jim J Xiao. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2021 11; 88(5):887-897. doi: 10.1007/s00280-021-04338-7. [PMID: 34370076]